Why these 4 ASX shares dropped lower today

In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has pushed notably higher again and is up 0.3% to 6,148 points.

Four shares that have been unable to follow the market higher today are listed below. Here’s why they have dropped lower:

The Creso Pharma Ltd (ASX: CPH) share price has tumbled almost 8% to $1.11 despite there being no news out of the pot stock. But considering the strong gains that the industry has made in recent days, I suspect profit-taking has started. I can’t help but feel that there’s a good chance that other pot stocks will follow suit.

The Northern Star Resources Ltd (ASX: NST) share price is down 2.5% to $6.00. Today’s decline is likely to be related to a slight decline in the gold price overnight after the U.S. dollar strengthened. The spot gold price is currently fetching US$1,318 an ounce. As I expect the U.S. dollar to strengthen as U.S. rates rise, I believe the gold price could continue to weaken as the year progresses.

The PAS Group Ltd (ASX: PGR) share price is 2.5% lower to 40 cents after the retail group released a trading update. According to the release, management advised that subdued consumer sentiment, industry wide traffic headwinds, and an elevated promotional environment have continued to way on its performance. As a result, like-for-like sales from its Review and Black Pepper brands are lower year-on-year.

The Sigma Healthcare Ltd (ASX: SIG) share price has continued its decline, falling 4.5% to 94 cents. Although there was no news out of the company, investors have been heading to the exits for some time due to the pharmacy chain operator and distributor’s deteriorating performance. I think investors ought to stay away from Sigma despite how cheap it may look.

If your portfolio needs a lift after these declines then look no further than these quality shares.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!